February 27, 2019 at 4:05 PM EST REDWOOD CITY, Calif., Feb. 27, 2019 (GLOBE NEWSWIRE) — Menlo Therapeutics Inc.(NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of...
December 10, 2018 at 7:00 AM EST Company to Conduct Conference Call and Webcast Today at 8:00am ET / 5:00am PT REDWOOD CITY, Calif., Dec. 10, 2018 (GLOBE NEWSWIRE) — Menlo Therapeutics Inc.(NASDAQ:...
November 16, 2018 at 8:30 AM EST REDWOOD CITY, Calif., Nov. 16, 2018 (GLOBE NEWSWIRE) — Menlo Therapeutics Inc.(NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of...
~ Phase 2 Data in Refractory Chronic Cough Expected in October 2018 ~ ~ Phase 2 Data in Psoriasis Expected December 2018 or January 2019 ~ ~ New Phase 2 Study in Chronic Pruritus of Unknown Origin Expected...
REDWOOD CITY, Calif., May 07, 2018 (GLOBE NEWSWIRE) — Menlo Therapeutics Inc. (NASDAQ:MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of...
Company to Host Conference Call Monday April 9 at 4:00am PT / 7:00am ET REDWOOD CITY, Calif., April 8, 2018 — Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on...
REDWOOD CITY, Calif., March 28, 2018 — Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant, for the treatment of pruritus...
REDWOOD CITY, Calif., February 20, 2018 — Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant, for the treatment of pruritus...
REDWOOD CITY, Calif., Jan. 29, 2018 (GLOBE NEWSWIRE) — Menlo Therapeutics Inc. (NASDAQ:MNLO) today announced the closing of the Company’s initial public offering of 8,050,000 shares of common stock...